Why Wealthy Investors Are Quietly Betting Big on AI and HealthTech

Jan de Vries · 2026-10-12

Investment ambitions across the EU for AI and HealthTech are expansive. The EU's InvestAI initiative aims to mobilize €200 billion (about $218 billion) for artificial intelligence, including funding for major AI infrastructure. The European Commission and the European Investment Bank Group have also launched BioTechEU to mobilize €10 billion (roughly $10.9 billion) for biotech and life sciences in 2026 and 2027. That investment push comes as AI and healthcare are also becoming increasingly popular among wealthy private investors globally. The UBS Global Family Office Report 2026, for example, found that 65% of family offices were already invested in AI, and 33% were allocated to AI-enabled healthcare. Below, we'll explore why so much private capital is moving toward AI and HealthTech. ### Investing in AI and HealthTech in 2026 The scale of the EU's investment and infrastructure plans shows how strategically important AI has become. Infrastructure is one of the clearest examples. In July 2026, the EU requested up to seven AI Gigafactories, backed by up to €10 billion (about $10.9 billion) in EU and national funding and expected to unlock at least €20 billion (around $21.8 billion) in additional private investment across the Union. Life sciences are also an important part of the EU economy, already contributing nearly €1.5 trillion (roughly $1.6 trillion) in value and supporting 29 million jobs. The EU is now trying to increase investment further through initiatives such as BioTechEU, which is designed to mobilize €10 billion (about $10.9 billion) for biotechnology and life sciences investment during 2026 and 2027. The European Commission's wider life sciences strategy also includes measures to make it easier to fund multi-country clinical trials and €300 million (around $327 million) to stimulate the procurement of life sciences innovations, including next-generation vaccines and affordable cancer solutions. As investment moves into high-growth sectors, investors can also explore private-market opportunities through firms that operate across venture capital, private equity, and real estate markets. ### AI and HealthTech Sector Growth The EU has a massive life sciences industry with major research institutions, healthcare systems, and rapidly expanding AI infrastructure, which helps explain investor interest. By April 2026, 19 AI Factories had been deployed across European supercomputers, supported by 13 regional AI Factory antennas, giving researchers, startups, and businesses greater access to AI computing capacity. EU and participating EuroHPC countries have committed more than €2.6 billion (about $2.8 billion) to the AI Factories and Antennas initiative. Then you've got the healthcare side. The European Health Data Space is designed to make health data easier to access and reuse securely across the EU for research, innovation, and regulatory purposes, creating potentially valuable infrastructure for areas such as medical research and AI development. Other EU projects include building specialist datasets, including Cancer Image Europe, which is expected to provide access to 60 million cancer images by the end of 2026, and the 1+ Million Genomes initiative, which aims to provide secure access to genomic and associated clinical data. Interestingly, the EU is also trying to move AI from research into clinical settings. In 2026, the European Commission made €9 million (about $9.8 million) available for two large-scale pilots of AI-powered medical imaging, covering technologies such as X-rays, CT scans, MRI, PET, and ultrasound. For investors, the attraction is that HealthTech is moving beyond laboratory research into real-world clinical testing and EU-backed deployment programs. ### Massive Capital Rotation From High-Net-Worth Investors It's difficult to track exactly what every high-net-worth individual is investing in. Much private investment isn't publicly disclosed. > "Family offices tell us they want sectors where policy tailwinds and real-world deployment line up. AI and HealthTech now sit at that intersection." That quote captures the mood. Investors aren't just chasing hype. They're following government commitments, data infrastructure, and clinical pilots that give these sectors a floor under the excitement. What makes this rotation notable is the timing. Public funding is de-risking early infrastructure, while private capital steps in to scale what works. For high-net-worth investors, that's a familiar playbook, just applied to newer markets. So the question isn't really whether AI and HealthTech will attract capital. It's how quickly the next wave of private money follows the public groundwork already being laid across Europe.